Patterns of Patient Recruitment in Clinical Studies on the Example of International Multicenter Clinical Studies (IMCTs)
https://doi.org/10.33380/2305-2066-2023-12-3-151-168
Abstract
Introduction. Patient recruitment is one of the main quantitative and qualitative characteristics of a clinical trial. As a quantitative characteristic, the recruitment of patients is, first of all, the final figure necessary to answer the researcher's question; as a qualitative characteristic, the recruitment of patients is a process subject to influence. The recruitment of patients in the center is determined by the rate per month and allows you to gain the statistical power of the protocol, and if the recruitment of patients does not reach the planned capacity, then the capacity may not be gained and this leads to the failure of the clinical trial. Failures in patient recruitment reported in the literature lead to more than 80 % of failed clinical trials of all phases. Patient recruitment as a process is influenced by various factors, and the authors identify recruitment predictors, recruitment facilitators, and barriers to patient recruitment.
Aim. To consider the general features and patterns of recruitment of patients in clinical trials on the example of international multicenter clinical trials.
Materials and methods. We analyzed the quantitative characteristics of patient recruitment in 4 clinical trials with successful recruitment.
Results and discussion. Despite the uniqueness of each protocol, the set of patients has its own patterns common to all clinical studies. It was studied, in particular, that the integrative assessment of the preliminary recruitment of patients by the researcher of the clinical center is not associated with an objective pool of patients and affects the rate of patient recruitment and targeted patient recruitment. We found that the number of clinical centers not recruiting patients in each study is at least 30 % of all centers involved. Three patient recruitment rates have also been identified that need to be considered when planning a clinical trial.
Conclusion. We have identified patterns in patient recruitment that will help in planning clinical trials.
About the Author
S. S. Milovanov
Sole entrepreneur Svyatoslav S. Milovanov
Russian Federation
Russian Federation
Moscow
References
1. Malgorzata M.-W. Patient-Centered Recruitment and Retention. Applied Clinical Trials. 2022. Available at: https://www.appliedclinicaltrialsonline.com/view/patient-centered-recruitment-and-retention. Accessed: 22.11.2022.
2. Crowther M. Phase 4 research: what happens when the rubber meets the road? Hematology. 2013;1:5–18. DOI: 10.1182/asheducation-2013.1.15.
3. Hwang T. J., Carpenter D., Lauffenburger J. C., Wang B., Franklin J. M., Kesselheim A. S. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine. 2016;176(12):1826–1833. DOI: 10.1001/jamainternmed.2016.6008.
4. Fogel D. B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemporary Clinical Trials Communications. 2018;11:156–164. DOI: 10.1016/j.conctc.2018.08.001.
5. Woodin K. E., Schneider J. C. The CRA's Guide to Monitoring Clinical Research. Third Edition. Falls Church: CenterWatch. 2011. 678 p.
6. Savateev A. V., Belotserkovsky M. V., Moscicka K., Palumbo D. Physical assessment as a cornerstone of a successful clinical trial. Kachestvennaya klinicheskaya praktika. 2013;(2):37–46. (In Russ.)
7. van den Bora R. M., Grobbee D. E., Oosterman B. J., Vaessen P. W. J., Roes K. C. B. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemporary Clinical Trials Communications. 2017;7:208–216. DOI: 10.1016/j.conctc.2017.07.004.
8. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Amsterdam: European Medicines Agency. 2018. 24 p. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf. Accessed: 22.11.2022.
9. Reuter S., Chiu G. R. How effective are site questionnaires in predicting site performance? J. Clin. Res. Best Pract. 2007;3(4).
10. Wild C. P., Weiderpass E., Stewart B. W., editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon: International Agency for Research on Cancer. 2020. Available at: http://publications.iarc.fr/586. Accessed: 20.11.2022.
11. Kaprin A. D., Starinsky V. V., Shakhzadova A. O. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen branch of the National Medical Research Center for Radiology of the Ministry of Health of Russia. 2021. 252 p. (In Russ.)
12. Merabishvili V. M., Diatchenko O. T. Lung Cancer Statistics (incidence, mortality, survival). Practical oncology. 2000;3:3–7. (In Russ.)
13. Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249. DOI: 10.3322/caac.21660.
14. Cox K., McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. European journal of cancer care. 2003;12(2):114–122. DOI: 10.1046/j.1365-2354.2003.00396.x.
15. Jones R. H., White H., Velazquez E. J., Shaw L. K., Pietrobon R., Panza J. A., Bonow R. O., Spoko G., O'Connor C. M., Rouleau J.-L. STICH (surgical treatment for ischemic heart failure) trial enrollment. J. Am. Coll. Cardiol. 2010;56(6):490–498. DOI: 10.1016/j.jacc.2009.11.102.
16. Bennette C. S., Ramsey S. D., McDermott C. L., Carlson J. J., Basu A., Veenstra D. L. Predicting low accrual in the National Cancer Institute's cooperative group clinical trials. Journal of the National Cancer Institute. 2016;108(2):djv324. DOI: 10.1093/jnci/djv324.
17. Bachenheimer B. J. F., Brescia B. A. Reinventing Patient Recruitment Revolutionary Ideas for Clinical Trial Success. New York: Routledge. 2007. 276 p.
18. Kibby M. Models for success. Good Clinical Practice Journal. 2005;12(6):31–33.
19. Yang E., O’Donovan C., Phillips J., Atkinson L., Ghosh K., Agrafiotis D. K. Quantifying and visualizing site performance in clinical trials. Contemporary Clinical Trials Communications. 2018;9:108–114. DOI: 10.1016/j.conctc.2018.01.005.
20. Wolf L. Expanding good recruitment practice. Journal of GXP compliance. 2007. P. 36–49.
21. Corrigan M. H., Glass H. E. Physician Participation in Clinical Studies and Subsequent Prescribing of New Drugs. Pharmacy and Therapeutics (P&T). 2005;30(1):60–66.
Supplementary files
|
|
1. Графический абстракт | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(2MB)
|
Indexing metadata ▾ | |
Review
For citations:
Milovanov S.S. Patterns of Patient Recruitment in Clinical Studies on the Example of International Multicenter Clinical Studies (IMCTs). Drug development & registration. 2023;12(3):151-168. (In Russ.) https://doi.org/10.33380/2305-2066-2023-12-3-151-168
Views:
5100
Email this article 